ClinicalTrialsFinder
RecruitingNCT03862677

Determining Prognostic Immune Markers in Patients With Ovarian Cancer

Sponsor

Leiden University Medical Center

Enrollment

300 participants

Start Date

Aug 15, 2020

Study Type

OBSERVATIONAL

Conditions

Epithelial Ovarian Cancer

Summary

The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).

Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria5

  • Patients with (suspicion of) primary or recurrent EOC with an indication for surgery, chemotherapy and/or immunotherapy.
  • Age ≥18 years.
  • WHO performance status 0-2.
  • Accessible for treatment and follow-up.
  • Written informed consent.

Exclusion Criteria4

  • Other active malignancy in past 5 years prior to entry into the study, except for treated non-melanoma skin cancer.
  • Any known severe infection like HIV, hepatitis A, B and C.
  • Receiving immune suppressive treatment.
  • Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.

Interventions

OTHERNo intervention

Observational study, no intervention

Locations(1)

Leiden University Medical Center

Leiden, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03862677

Related Trials

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT

NCT064125101 location

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)

NCT074809541 location

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT069150257 locations

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT0689033850 locations

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT074326331 location